Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.580
+0.170 (3.85%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Arbutus Biopharma Employees
Arbutus Biopharma had 19 employees as of December 31, 2025. The number of employees decreased by 25 or -56.82% compared to the previous year.
Employees
19
Change (1Y)
-25
Growth (1Y)
-56.82%
Revenue / Employee
$10,076,053
Profits / Employee
$8,458,947
Market Cap
904.72M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Geron | 258 |
| Alpha Tau Medical | 121 |
| Solid Biosciences | 121 |
| Janux Therapeutics | 108 |
| Odyssey Therapeutics | 100 |
| Annexon | 93 |
| Theravance Biopharma | 90 |
| Alto Neuroscience | 68 |
ABUS News
- 6 weeks ago - Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Arbutus Biopharma Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Arbutus Biopharma Earnings release: Q1 2026 - Filings
- 2 months ago - Arbutus Biopharma granted Fast Track designation for imdusiran - TheFly
- 2 months ago - Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - GlobeNewsWire
- 2 months ago - Arbutus Biopharma Proxy statement: Proxy filing - Filings
- 2 months ago - Arbutus Biopharma Proxy statement: Proxy filing - Filings
- 2 months ago - Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies - TheFly